Treatment of Renal Cell Carcinoma: Current Status and Future Directions

Overview

Journal CA Cancer J Clin

Publisher Wiley

Specialty Oncology

Date 2017 Sep 30

PMID 28961310

Citations 458

Authors

Pedro C Barata

Brian I Rini

Affiliations

Soon will be listed here.

Abstract

Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agents-including molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine-protein kinase receptors; and an immune-checkpoint inhibitor-have been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507-524. © 2017 American Cancer Society.

Citing Articles

Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies.

Wu G, Chen C, Chang J, Fazlollahi F, Makary M Cancers (Basel). 2025; 17(5).

PMID: 40075574 PMC: 11899649. DOI: 10.3390/cancers17050726.

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.

RNA-Based Therapies in Kidney Diseases.

Hu L, Jin T, Zhang N, Ding J, Li L J Inflamm Res. 2025; 18:3143-3160.

PMID: 40059951 PMC: 11890006. DOI: 10.2147/JIR.S505252.

MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker.

Wang H, Chen Y, Yang Y, Song R, Gu S, Cao X Cell Death Dis. 2025; 16(1):102.

PMID: 39956807 PMC: 11830799. DOI: 10.1038/s41419-025-07427-0.

Machine learning identification of a novel vasculogenic mimicry-related signature and FOXM1's role in promoting vasculogenic mimicry in clear cell renal cell carcinoma.

Xu C, Zhang S, Lv J, Cao Y, Chen Y, Sun H Transl Oncol. 2025; 53:102312.

PMID: 39904282 PMC: 11847097. DOI: 10.1016/j.tranon.2025.102312.